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Helicobacter pylori with stronger intensity of CagA
phosphorylation lead to an increased risk of
gastric intestinal metaplasia and cancer
Chiao-Hsiung Chuang1, Hsiao-Bai Yang2, Shew-Meei Sheu3, Kuei-Hsiang Hung3, Jiunn-Jong Wu3, Hsiu-Chi Cheng1,4
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Abstract
Background: Nearly all Taiwanese H. pylori stains are cagA-genopositive and encode CagA protein. In this study,
we evaluated whether different intensity of tyrosine phosphorylated-CagA (p-CagA) had an impact on the clinical
diseases and histological outcomes in this area.
Results: We enrolled 469 dyspeptic patients and prospectively obtained the gastric biopsy specimens and the H.
pylori isolates. These patients were categorized according to the clinical diseases, such as duodenal ulcer, gastric
ulcer, gastric cancer, and gastritis with or without intestinal metaplasia. Their gastric specimens were reviewed by
the updated Sydney’s system. Furthermore, a total of 146 patients were randomly selected from each clinical
category for evaluation of their isolates’ p-CagA intensity by in vitro AGS cells co-culture. The p-CagA was sparse in
30 (20.5%), weak in 59 (40.5%), and strong in 57 (39%) isolates. The isolates from the patients of gastric cancer or
gastritis with intestinal metaplasia had stronger p-CagA intensity than those of gastritis without intestinal
metaplasia (p ≤ 0.002). Moreover, the patients infected with isolates with strong or weak p-CagA intensity had a
higher risk of gastric intestinal metaplasia (p < 0.05, odds ratio 3.09~15.26) than those infected with sparse p-CagA
isolates.
Conclusions: Infection with H. pylori stains with stronger p-CagA intensity may lead to an increased risk of gastric
intestinal metaplasia and cancer.
Keywords: H. pylori cagA, CagA phosphorylation, intestinal metaplasia, gastric cancer
Background
The cagA gene encoded CagA protein is a well-known
virulent factor of Helicobacter pylori, which is asso-
ciated with an increased risk of peptic ulcer or even
gastric cancer [1-4]. The CagA protein can be tyrosine
phosphorylated in the gastric epithelial cells via the
type IV secretion system translocation [5]. The phos-
phorylated-CagA (p-CagA) mediates interleukin-8
secretion, enhances gastric inflammation, and clinical
diseases [5-8]. As shown in the Mongolian gerbil mod-
els, H. pylori isolates with functional type IV secretion
system could induce more CagA phosphorylation and
severer gastric inflammation and intestinal metaplasia
(IM) [9,10]. However, there is no adequate clinical evi-
dence in a setting to support the relationship between
CagA phosphorylation intensity and the risk of gastric
carcinogenesis.
In the western countries, about 70% or less of clinical
H. pylori strains are cagA-genopositive [11,12]. In con-
trast, in the eastern countries, such as in Taiwan, there
is a nearly 100% prevalence of cagA-vacA-babA2 triple-
positive H. pylori strains [13-15]. Moreover, most strains
in East-Asia, and also Taiwan, encoded CagA contain
EPIYA-ABD motif [16-18]. Our previous data supported
100% positive of some genes which are encoded from
cag pathogenicity island (PAI), such as cagC, cagE, cagF,
cagN, and cagT [19]. Accordingly, because of the uni-
versal presence of genes in cag-PAI in Taiwan, this
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region should be suitable to answer whether different p-
CagA intensity are related to different clinicopathologic
outcomes of H. pylori infections. The study is highly ori-
ginal to illustrate the p-CagA intensity could be diverse
among the cagA-positive H. pylori isolates, and to sup-
port H. pylori with stronger p-CagA intensity can
increase the risk of gastric carcinogenesis.
Methods
Patients and study design
Patients with recurrent dyspepsia symptoms, who
received upper gastrointestinal endoscopy, were conse-
cutively enrolled, once they were proven to have a H.
pylori infection defined by a positive result of culture.
None of them had a previous history of anti-H. pylori
therapy. For each patient, the gastric biopsies were
obtained during the endoscopy for H. pylori culture and
histological analysis. This study were approved by
‘Human Experiment and Ethics Committee of National
Cheng Kung University Hospital’ (ER-97-245) and all
the patients signed the informed consents before
enrollment.
A total of 469 patients (264 women and 205 men;
mean age 48.1 years) were enrolled, including 26 with
gastric cancer, 64 with gastric ulcer, 131 with duodenal
ulcer, 209 with gastritis & without IM and 39 with gas-
tritis & IM. From each category, 32 isolates were ran-
domly sampled (the cancer group had just 26 isolates
and all were selected). A total of 154 isolates were
sampled, but 8 stored strains could not be successfully
subcultured after refrigeration. Accordingly, 146 strains
were finally obtained from patients with duodenal ulcer
(n = 31), gastric ulcer (n = 32), gastric cancer (n = 24),
gastritis with IM (n = 28), and gastritis without IM (n =
31). These 146 H. pylori isolates were analyzed for the
cagA-genotype by polymerase chain reaction and for the
intensity of p-CagA by in vitro co-culture with AGS
cells (a human gastric adenocarcinoma epithelial cell
line); further the p-CagA intensity was defined as strong,
weak, or sparse. Besides, in each patient, their gastric
biopsies taken from both antrum and corpus for histol-
ogy were reviewed by the updated Sydney’s system.
Histological analysis of the gastric specimens
Each gastric sample was stained with haematoxylin and
eosin as well as with modified Giemsa stains to analyze
for H. pylori density (HPD, range 0-5) and H. pylori-
related histology by the updated Sydney’s system. The
histological parameters included acute inflammation
score (AIS, range 0-3; 0: none, 1: mild, 2:moderate, 3:
severe), chronic inflammation score (CIS, range 1-3; 1:
mild, 2: moderate, 3: severe), mucosal atrophy, and IM
as applied in our previous studies [20,21]. For each
patient, the presence of atrophy or IM was defined as a
positive histological finding in any specimen from the
antrum or corpus. In each patient, the total HPD, AIS,
and CIS were the sum of each score of the gastric speci-
mens from antrum and corpus, and thus ranged from 0-
10, 0-6, and 2-6, respectively. Based on the sum of HPD,
the patients were categorized as loose (score ≤ 5), mod-
erate (score within 6-8), and dense (score ≥ 9) H. pylori
colonization, respectively. For the sum of AIS, mild,
moderate, and severe acute inflammations were defined
with scores ≤1, 2-3, or ≥4, respectively. Based on the
sum of CIS, mild, moderate, and severe chronic inflam-
mations were defined with scores ≤3, 4-5, or 6,
respectively.
Based on the specimens collected from both the
antrum and corpus within the same patient, the topo-
graphical distribution of chronic gastritis was defined as
follows: 1) very limited chronic gastritis, if the CIS
scored was 1 for both antrum and corpus; 2) antrum-
predominant gastritis, if the CIS score of the antrum
was higher than the score of the corpus; and 3) corpus-
predominant gastritis, if the corpus CIS was equal to or
higher than that of the antrum [21].
Analysis of cagA genotype and type IV secretion system
function of H. pylori
All H. pylori isolates were re-sorted by culture as
applied in our previous publications [14,15]. The geno-
mic DNA of these collected isolates was then extracted
for polymerase chain reaction to verify the cagA-geno-
type by primers used in our published article [19]. To
analyze the p-CagA intensity of each strain, H. pylori
strains (2 × 108 cells) were suspended in 0.5 mL of
phosphate-buffered saline (PBS) and were co-cultured
with 2 × 106 AGS cells at a multiplicity of infection
(MOI) of 100 for 5 hours. Afterward, the culture med-
ium was removed and the AGS cells were lysed after
five times washing with PBS. The AGS lysates were
applied to SDS-PAGE gel electorphoresis and trans-
ferred to membranes for western blots analysis. A phos-
phorylated tyrosine antibody and anti-actin antibody
(Santa Cruz Biotechnology, Inc, Santa Cruz, CA) were
used to detect the p-CagA and b-actin proteins. A clini-
cal H. pylori strain (Hp830) which had a strong p-CagA
band in the western blots was used as reference. In each
western blots procedure, 7-9 clinical strains and the
reference strain were analyzed in the same run. The
relative immunoblot density of the p-CagA and b-actin
proteins were quantitated by scanning the images on a
gel analysis system (BioSpectrum AC Imaging System,
Vision Work LS software, Upland, CA) for each strain
and defined as [p-CagA] and [Bactin]. The amount of p-
CagA and b-actin proteins of the reference strain in the
same run were also semi-quantified as reference and
defined as [p-CagA-ref] and [Bactin-ref]. The p-CagA
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intensity of each strain was calculated by the formula: p-
CagA value = ([p-CagA]/[Bactin])/([p-CagA-ref]/[Bactin-
ref]). Strains with a p-CagA value <0.2, 0.2-0.8, and >0.8
were defined as sparse, weak, and strong p-CagA inten-
sity. The immunoblot gel imaging of the representative
strain in each subgroup and the reference strain
(Hp830) were showed in Figure 1.
Statistical analysis
SPSS software version 12.0 for Windows (SPSS Inc.,
Chicago, IL) was used for the statistical analysis. The
differences in the p-CagA intensity among the sub-
groups of patients were analyzed by Pearson chi-square
test. The odds ratio on the risk of IM and corpus-predo-
minant gastritis between the different subgroups were
analyzed by the logistical regression. All tests were two-
tailed, and a p value less than 0.05 were considered
significant.
Results
H. pylori isolates with diverse p-CagA intensity
From the 469 patients, we sampled 146 strains for the
analysis of the p-CagA intensity. The clinical character-
istics of these patients were shown in Table 1. In each
sampled group, age and gender were matched between
the sampled patients and the entire group of patients (p
= NS). All of the 146 enrolled H. pylori isolates were
cagA-genopositive and the p-CagA intensity was sparse
in 30 (20.5%), weak in 59 (40.5%), and strong in 57
(39%) isolates.
Stronger p-CagA intensity may lead to intestinal
metaplasia & gastric cancer
In Figure 2, the H. pylori strains of gastric cancer or
gastritis with IM patients had stronger p-CagA intensity
than those of gastritis without IM (54.2% & 53.6% vs.
12.9%, p ≤ 0.002). There was also a trend that the H.
pylori isolates from cancer or IM patients had relatively
stronger p-CagA intensity then the subgroups of gastric
and duodenal ulcer, but the difference was not signifi-
cant. Moreover, the p-CagA intensity was not different
among the subgroups of gastric ulcer, duodenal ulcer,
and gastritis without IM. In Figure 3, the patients were
separated according to having cancer risk or not. The
isolates from the patients with cancer or IM had stron-
ger p-CagA intensity than those from non-cancer/IM
Figure 1 The p-CagA and b-actin immunoblot gel imaging of
the reference strains (Hp830) and the representative strain in
each subgroup.
Table 1 The clinical characteristics between all patients with isolated H. pylori strains and the selected patients for
analysis of the p-CagA intensity of the strains
Patients with H. pylori cultures (n = 469) Selected patients for p-CagA analysis (n = 146) p value*
Age (year [mean ± SD]) 48.1 ± 14.2 50.4 ± 16.3 NS
Gender (F/M) 264/205 73/73 NS
Endoscopic diagnosis (year; n(F/M))
Gastritis
- without intestinal metaplasia 44.3; 209 (137/72) 41.2; 31 (18/13) NS
- with intestinal metaplasia 54.5; 39 (29/10) 57.0; 28 (22/6) NS
Duodenal ulcer 48.0; 131 (68/63) 46.6; 31 (14/17) NS
Gastric ulcer 51.3; 64 (17/47) 49.5; 32 (7/25) NS
Gastric cancer 60.4; 26 (13/13) 60.6; 24 (12/12) NS
* Either the age or the gender was matched between the 146 selected patients and the entire patients in each sampled groups (Pearson chi-square test for
gender & Student’s t test for age analysis).
Figure 2 The p-CagA intensity of the strains isolated from
patients with different clinical categories. The strains isolated
from patients of gastric cancer or gastritis with intestinal metaplasia
had stronger p-CagA intensity than those from gastritis without
intestinal metaplasia patients (*p = 0.001, +p = 0.002; Pearson chi-
square test). IM = intestinal metaplasia.
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patients (p < 0.001). Furthermore, the patients with can-
cer risk had higher gastric inflammation or atrophy (p <
0.001).
The impacts of p-CagA intensity on gastric IM were
analyzed in the non-cancer patients. Twenty-four out of
the 47 patients (51.1%) infected with strong p-CagA
strains had gastric IM. In contrast, for those with weak
and sparse p-CagA, 35.4% (17 out of 48) and 11.1% (3
out of 27) patients had gastric IM. Accordingly, the
patients infected with stronger p-CagA strains had
higher prevalence of IM in the gastric specimens (p =
0.003). Moreover, the odds ratios of age, gender and p-
CagA intensity on the gastric IM were showed in Table
2. As compared to those infected with strains with
sparse p-CagA intensity, the crude odds ratio to have
IM was 4.38 for those with weak p-CagA intensity, and
increased to 8.34 for those with strong p-CagA intensity.
Based on the logistic regression analysis to adjust the
age, gender, and clinical diagnoses, the odds ratios to
have IM were 3.93 for the patients infected with weak
p-CagA intensity isolates and 10.45 for those with
strong p-CagA intensity.
Correlation between H. pylori p-CagA intensity and
gastric histological features
In Figure 4, this study also analyzed whether there were
an association between the p-CagA intensity and the
severity of gastric inflammation in histology. The
patients infected with H. pylori isolates with stronger p-
CagA intensity may have more severe acute inflamma-
tion (p = 0.04) and also chronic inflammation (p =
0.002). Nevertheless, the p-CagA intensity of H. pylori
isolates was not associated with the HPD or gastric atro-
phy (p > 0.05).
In Figure 5, a higher proportion of patients infected
with a strain with strong p-CagA intensity had corpus-
predominant gastritis (59.6%), as compared to those
infected with strains with weak (40%) or sparse (25.9%)
p-CagA intensity (p = 0.001). The adjusted odds ratio
for age, gender, and clinical diagnoses by logistic regres-
sion was 3.15 (1.07~9.31) for patients infected with H.
pylori with strong p-CagA intensity and 1.49 (0.51~4.35)
for those infected with strains with weak p-CagA inten-
sity, as compared with those with sparse p-CagA
intensity.
Discussion
This study shows the clinical impacts of H. pylori p-
CagA intensity on the risk of gastric carcinogenesis. In
Taiwan, the H. pylori isolates have universal presence of
genes in cag-PAI and expression of CagA [13-16]. On
the basis of the semi-quantitative analysis of the translo-
cated p-CagA bands in the western blots, the strains in
this study have diverse intensity of p-CagA. To further
evaluate the clinical impact of the diverse p-CagA inten-
sity on the clinical outcome, we selected a clinical strain
with marked p-CagA to serve as reference index to sub-
group the 146 collected strains according to their p-
CagA intensity into strong, weak, or sparse. Based on
this categorization, this study showed that H. pylori iso-
lates with stronger p-CagA were correlated to more
severe gastric inflammation and an increased risk of gas-
tric IM and cancer.
The possible factors to affect CagA phosphrylation
include the cagA genotype, type IV secretion system, the
CagA EPIYA-repeat motif of the strain, and the
Figure 3 Comparing with the isolates from patients without
IM/cancer, those from cancer or IM patients had significantly
stronger p-CagA intensity, more gastric atrophy, severer acute
or chronic inflammation, but had no difference in H. pylori
density. (The black, grey & white bars indicate: strong, weak, &
spare p-CagA; dense, moderate & loose H. pylori density; severe,
moderate & mild inflammation; with & without atrophy.)
Table 2 The impacts of the p-CagA intensity of H. pylori
on the gastric intestinal metaplasia in the 122 selected
non-cancer patients by stratified analysis and logistical
regression
Odd ratio (95% CI)
Crude: Age < 50 years 1
< 50 years 8.14 (3.49~18.98)
Gender - Male 1
- Female 2.36 (1.12~5.11)
p-CagA - Sparse 1
- Weak 4.38 (1.15~16.72)
- Strong 8.34 (2.21~31.55)
Age and gender adjusted
Sparse p-CagA 1
Weak p-CagA 3.67 (0.93~14.37)
Strong p-CagA 8.44 (2.08~34.12)
Age, gender and disease adjusted
Sparse p-CagA 1
Weak p-CagA 3.93 (0.92~16.94)
Strong p-CagA 10.45 (2.25~48.48)
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adhesion phenotype of the epithelial cell [22-27]. Animal
studies have shown that mutant strains of CagA, CagE,
or CagY could reduce the gastric inflammation after
infection [10,28]. Moreover, the CagA EPIYA poly-
morphism has also a causal role in clinical outcome
[18,29]. These data support that these factors are all
important in the H. pylori related gastric inflammation
via CagA phosphorylation. However, there is no pre-
vious human study to evaluate the impact of the p-
CagA intensity on gastric histological changes. Thus,
this study is first time to disclose that strains isolated
from gastric cancer and IM patients had a stronger p-
CagA function as compared with strain from gastritis
without IM patients (Figure 2). However, those were not
significantly stronger than the strains from gastric or
duodenal ulcer. This result can be explained that the IM
and non-IM were both included into the gastric and
duodenal ulcer subgroups to dilute the significance. This
explanation may be also supported by a study showing
that the intensities of p-CagA were not significantly dif-
ferent among different clinical diseases [22].
Moreover, as shown in Figure 3, the isolates from
patients with cancer risk (i.e, patients with IM or can-
cer) had significantly stronger p-CagA intensity than
those from patients without cancer risk (p < 0.001).
This data further support that strong p-CagA increase
the risk of developing gastric carcinogenesis from H.
pylori infection. Furthermore, the patients with IM or
cancer had severer acute and chronic inflammation in
gastric histology. Also shown in Figure 4, the patients
infected with stronger p-CagA H. pylori strains could
correlate with severer acute or chronic gastritis (p <
0.05). This indicated that the p-CagA intensity is closely
Figure 4 The H. pylori density, inflammation and atrophy by gastric histology among the 146 patients infected with H. pylori isolates
with different p-CagA intensity. The isolates with stronger p-CagA intensity were significantly associated with more severe acute inflammation
(p = 0.01) and chronic inflammation (p = 0.005) but not with H. pylori density or gastric atrophy (p = NS) (Pearson chi-square test).
Figure 5 The patients infected with strains with strong or
weak p-CagA intensity had more corpus-predominant gastritis
than those infected with strains with sparse p-CagA intensity
(p = 0.001, Pearson chi-square test).
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related to provoke gastric inflammation in both patients
with and without gastric cancers.
It is well known that the H. pylori-infected host has an
increased risk of developing gastric cancer, once the gas-
tric histology reveals a corpus-predominant pattern or a
precancerous change such as IM [30-33]. We, therefore,
further validated whether the infection of patients with
strong p-CagA H. pylori strains is associated with an
increased risk of such histological changes. As shown in
Figure 5, strains with stronger p-CagA caused more
often corpus-predominant gastritis (p = 0.001). Also
shown in Figure 2, the strains isolated from patients of
gastritis with IM had a significantly stronger p-CagA
than those from gastritis patients without IM (p =
0.002). These data supported the hypothesis that the p-
CagA intensity of H. pylori isolates is closely related
with the presence of IM.
In this study, instead of using all 469 stored strains,
we systemically sampled 146 strains from our H. pylori
database for the analysis of the p-CagA intensity. Both
crude and adjusted odds ratio of the p-CagA intensity
on IM were computed by logistical regression for the
possible confounding factors, such as age, gender, and
clinical disease. As shown in Table 2, the older age,
female and stronger p-CagA had higher risk of having
IM. In the multivariable regression, patients infected
with H. pylori strains with strong and weak p-CagA had
a 10.45 and 3.93 times higher risk of having IM than
those infected with strains with sparse p-CagA intensity.
The study is noteworthy in showing that, in a 100%
cagA-genopositive area, the p-CagA intensity could be an
important independent factor closely associated with an
increased risk of precancerous changes such as IM. How-
ever, the assessment of the p-CagA intensity in H. pylori
isolates may not be widely available for clinical application.
Accordingly, it is worth conducting future studies to
determine biomarkers to indirectly evaluate the p-CagA
intensity of the infected host. Once a biomarker is avail-
able, it will be helpful to identify patients infected with H.
pylori strains with stronger p-CagA intensity, to determine
the risk of gastric carcinogenesis in non-cancer patients,
and then select these patients for earlier treatment.
Conclusions
In conclusion, patients infected with a H. pylori strain
with stronger CagA phosphorylation ability have more
severe chronic gastric inflammation with an increased
risk to have corpus-predominant gastritis, gastric intest-
inal metaplasia, and cancer.
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